Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
6.140
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
April 13, 2023
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 06, 2023
Via
Benzinga
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023
March 31, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
March 29, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients
March 21, 2023
Via
Benzinga
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
March 29, 2023
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
Via
News Direct
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
March 29, 2023
By David Willey, Benzinga
Via
TheNewswire.com
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
March 28, 2023
Coya Therapeutics (NASDAQ: COYA) has just reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis (ALS).
Via
Benzinga
Coya Therapeutics: This BioPharma Company Has Some Big News To Share
March 27, 2023
Howard Burman, Ph.D, CEO & Chairman of Coya Therapeutics Inc (NASDAQ: COYA), was a guest on Benzinga’s All Access.
Via
Benzinga
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
March 27, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
March 23, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
March 23, 2023
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Via
News Direct
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET
March 23, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
March 22, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Topics
Death
Exposures
Death
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
March 22, 2023
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Via
News Direct
Topics
Death
Exposures
Death
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
March 22, 2023
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.
Via
Benzinga
Coya Therapeutics' COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
March 21, 2023
Coya Therapeutics, Inc. (NASDAQ: COYA) recently reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to...
Via
Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
March 21, 2023
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Via
News Direct
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
March 21, 2023
By Kenneth Adams, Benzinga
Via
TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 21, 2023
Via
Benzinga
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET
March 21, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
March 21, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302
March 20, 2023
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.
Via
Benzinga
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
March 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET
March 09, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
March 06, 2023
By David Willey, Benzinga
Via
TheNewswire.com
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
March 06, 2023
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
Via
News Direct
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
March 03, 2023
Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field.
Via
Benzinga
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
February 28, 2023
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary...
Via
TheNewswire.com
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
February 28, 2023
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
Via
News Direct
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.